Compare Stocks → Move Your Money Before May 1 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYTXNASDAQ:DCTH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTXCytori Therapeutics$1.67+3.7%$0.20$0.20▼$0.75$36.90M1.96915,302 shs5,262 shsDCTHDelcath Systems$5.30+0.8%$4.54$2.25▼$7.99$134.83M0.53223,650 shs165,013 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTXCytori Therapeutics0.00%-9.35%-13.98%-16.32%+607.34%DCTHDelcath Systems-3.49%+12.03%+14.10%+18.47%-7.56%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTXCytori TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADCTHDelcath Systems3.9855 of 5 stars3.55.00.00.03.84.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTXCytori TherapeuticsN/AN/AN/AN/ADCTHDelcath Systems3.00Buy$18.50249.06% UpsideCurrent Analyst RatingsLatest CYTX and DCTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTXCytori Therapeutics$3.67M10.05N/AN/A$0.35 per share4.76DCTHDelcath Systems$2.07M65.14N/AN/A$0.72 per share7.36Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTXCytori Therapeutics-$12.63MN/A0.00∞N/A-242.60%-272.70%-56.23%N/ADCTHDelcath Systems-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)Latest CYTX and DCTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 23DCTHDelcath Systems-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTXCytori TherapeuticsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTXCytori Therapeutics0.390.460.30DCTHDelcath SystemsN/A2.262.06OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTXCytori Therapeutics2.62%DCTHDelcath Systems61.12%Insider OwnershipCompanyInsider OwnershipCYTXCytori Therapeutics0.66%DCTHDelcath Systems17.94%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTXCytori Therapeutics3722.16 millionN/ANot OptionableDCTHDelcath Systems7625.44 million20.88 millionOptionableCYTX and DCTH HeadlinesSourceHeadlineDelcath Systems (NASDAQ:DCTH) Trading 1.6% Higher americanbankingnews.com - April 24 at 2:20 AMHow Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%zacks.com - April 23 at 10:56 AMDelcath Systems gets grant for optimizing chemotherapeutic agent filtration media pair for cancer treatmentpharmaceutical-technology.com - April 18 at 8:59 AMHead to Head Survey: Sharps Technology (NASDAQ:STSS) & Delcath Systems (NASDAQ:DCTH)americanbankingnews.com - April 16 at 2:20 AMCan Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?zacks.com - April 5 at 10:56 AMDelcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - April 4 at 1:59 PMDelcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - April 4 at 8:59 AMDelcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?zacks.com - April 2 at 1:01 PMShort Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Increases By 8.0%marketbeat.com - April 2 at 6:13 AMHC Wainwright Comments on Delcath Systems, Inc.'s Q1 2025 Earnings (NASDAQ:DCTH)marketbeat.com - March 31 at 1:48 AMDelcath Systems, Inc. (NASDAQ:DCTH) Forecasted to Earn Q1 2025 Earnings of ($0.25) Per Sharemarketbeat.com - March 29 at 8:53 AMDelcath Systems (NASDAQ:DCTH) Upgraded to Sell at StockNews.commarketbeat.com - March 27 at 11:16 PMAnalysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)markets.businessinsider.com - March 27 at 11:48 AMDelcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 11:48 AMDelcath Systems (NASDAQ:DCTH) Posts Earnings Resultsmarketbeat.com - March 27 at 9:30 AMDelcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancementsfinance.yahoo.com - March 26 at 9:50 AMDelcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 26 at 9:41 AMDelcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Updatefinanznachrichten.de - March 26 at 9:02 AMDelcath Systems GAAP EPS of -$0.48, revenue of $0.54Mmsn.com - March 26 at 9:02 AMDelcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Updateprnewswire.com - March 26 at 7:30 AMDelcath Systems Q4 2023 Earnings Previewmsn.com - March 25 at 6:00 PMInsiders of Delcath Systems Getting Good Value On Their US$736.5k Investmentfinance.yahoo.com - March 23 at 9:44 AMInsider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) Director Acquires 26,882 Shares of Stockinsidertrades.com - March 21 at 10:02 AMDelcath Systems Closes $7 Million Private Placementprnewswire.com - March 20 at 8:15 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCytori TherapeuticsNASDAQ:CYTXCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Delcath SystemsNASDAQ:DCTHDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
